Portolan Capital Management LLC Sells 12,687 Shares of United Therapeutics Corporation $UTHR

Portolan Capital Management LLC trimmed its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 41.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,076 shares of the biotechnology company’s stock after selling 12,687 shares during the quarter. Portolan Capital Management LLC’s holdings in United Therapeutics were worth $7,578,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. AE Wealth Management LLC lifted its stake in shares of United Therapeutics by 7.6% in the 2nd quarter. AE Wealth Management LLC now owns 864 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 61 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of United Therapeutics by 147.2% during the 2nd quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 212 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of United Therapeutics by 6.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 16,833 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 1,006 shares in the last quarter. Finally, Candriam S.C.A. grew its position in United Therapeutics by 5.0% during the 2nd quarter. Candriam S.C.A. now owns 83,211 shares of the biotechnology company’s stock worth $23,912,000 after acquiring an additional 3,998 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.6%

Shares of NASDAQ:UTHR opened at $536.12 on Friday. The firm has a market cap of $23.50 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12. The business has a fifty day simple moving average of $486.67 and a 200 day simple moving average of $460.13.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $6.19 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $496.30, for a total value of $11,166,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 338,947 shares of company stock worth $165,516,573 in the last ninety days. 10.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on UTHR shares. Wells Fargo & Company upped their target price on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. TD Cowen boosted their price target on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $548.09.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.